Published in Leuk Res on March 04, 2008
Is everything known in all faces of iceberg in PRAME? Leuk Res (2008) 0.79
Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods (2001) 414.27
Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc Natl Acad Sci U S A (2006) 3.70
The human tumor antigen PRAME is a dominant repressor of retinoic acid receptor signaling. Cell (2005) 2.73
Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. Immunity (1997) 2.71
Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. N Engl J Med (2001) 2.65
Gene expression in Wilms' tumor mimics the earliest committed stage in the metanephric mesenchymal-epithelial transition. Am J Pathol (2002) 2.17
Phase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B-cell malignancies. J Clin Oncol (2005) 2.16
Optimization of quantitative real-time RT-PCR parameters for the study of lymphoid malignancies. Leukemia (2003) 2.12
Efficient identification of novel HLA-A(*)0201-presented cytotoxic T lymphocyte epitopes in the widely expressed tumor antigen PRAME by proteasome-mediated digestion analysis. J Exp Med (2001) 1.50
PRAME, a gene encoding an antigen recognized on a human melanoma by cytolytic T cells, is expressed in acute leukaemia cells. Br J Haematol (1998) 1.43
The tumor-associated antigen PRAME is universally expressed in high-stage neuroblastoma and associated with poor outcome. Clin Cancer Res (2004) 1.30
Expression and activity of NOX5 in the circulating malignant B cells of hairy cell leukemia. J Immunol (2005) 1.27
Prevalence and prognostic and predictive relevance of PRAME in breast cancer. Breast Cancer Res Treat (2007) 1.22
Heterogeneous expression of the tumor-associated antigens RAGE-1, PRAME, and glycoprotein 75 in human renal cell carcinoma: candidates for T-cell-based immunotherapies? Cancer Res (1998) 1.17
Comparison of medulloblastoma and normal neural transcriptomes identifies a restricted set of activated genes. Oncogene (2003) 1.14
mRNA expression of leukemia-associated antigens in patients with acute myeloid leukemia for the development of specific immunotherapies. Int J Cancer (2004) 1.12
Clinical implications of PRAME gene expression in childhood acute myeloid leukemia. Cancer Genet Cytogenet (2002) 1.12
Expression analysis of stage III serous ovarian adenocarcinoma distinguishes a sub-group of survivors. Eur J Cancer (2006) 1.10
Minimal residual disease detection in hairy cell leukemia. Comparison of flow cytometric immunophenotyping with clonal analysis using consensus primer polymerase chain reaction for the heavy chain gene. Am J Clin Pathol (2003) 1.09
The cancer germ-line genes MAGE-1, MAGE-3 and PRAME are commonly expressed by human myeloma cells. Eur J Immunol (2000) 1.07
Hairy cell leukemia: an update. Curr Opin Hematol (2003) 1.06
Quantitative monitoring of the PRAME gene for the detection of minimal residual disease in leukaemia. Br J Haematol (2001) 1.04
Common features and differences in the transcriptome of large cell anaplastic lymphoma and classical Hodgkin's lymphoma. Haematologica (2006) 1.04
Epigenetic regulation of PRAME gene in chronic myeloid leukemia. Leuk Res (2007) 1.04
PRAME mRNA levels in cases with acute leukemia: clinical importance and future prospects. Am J Hematol (2005) 0.99
PRAME gene expression in childhood acute lymphoblastic leukemia. Cancer Genet Cytogenet (2002) 0.97
Identification of cancer-testis genes expressed by melanoma and soft tissue sarcoma using bioinformatics. Cancer Immun (2005) 0.97
Hypomethylation of PRAME is responsible for its aberrant overexpression in human malignancies. Genes Chromosomes Cancer (2007) 0.95
Tumor-associated antigen preferentially expressed antigen of melanoma (PRAME) induces caspase-independent cell death in vitro and reduces tumorigenicity in vivo. Cancer Res (2005) 0.94
Expression of cancer testis antigens in head and neck squamous cell carcinomas. Head Neck (2006) 0.92
PRAME mRNA levels in cases with chronic leukemia: Clinical importance and review of the literature. Leuk Res (2006) 0.91
Expression of RHAMM/CD168 and other tumor-associated antigens in patients with B-cell chronic lymphocytic leukemia. Int J Oncol (2006) 0.90
PRAME is a membrane and cytoplasmic protein aberrantly expressed in chronic lymphocytic leukemia and mantle cell lymphoma. Leuk Res (2006) 0.90
Minimal residual disease in hairy cell leukemia patients assessed by clone-specific polymerase chain reaction. Clin Cancer Res (2006) 0.89
Real-time RT-PCR quantification of PRAME gene expression for monitoring minimal residual disease in acute myeloblastic leukaemia. Clin Chem Lab Med (2006) 0.89
Somatic hypermutation and VH gene usage in hairy cell leukaemia. Br J Haematol (2006) 0.87
V(H) gene analysis of hairy cell leukemia reveals a homogeneous mutation status and suggests its marginal zone B-cell origin. Leukemia (2004) 0.86
The expression of PRAME in chronic lymphoproliferative disorders. Leuk Res (2003) 0.81
Quantitative assessment of PRAME expression in diagnosis of childhood acute leukemia. Leuk Res (2006) 0.79
[Expression of PRAME gene in multiple myeloma]. Ter Arkh (2004) 0.79
Immunoglobulin light chain repertoire in hairy cell leukemia. Leuk Res (2007) 0.78
Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood (2010) 7.25
The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia. Blood (2010) 5.95
Immunotoxin therapy of cancer. Nat Rev Cancer (2006) 3.93
Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers. Clin Cancer Res (2007) 3.30
Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol (2009) 3.13
IL-7 administration to humans leads to expansion of CD8+ and CD4+ cells but a relative decrease of CD4+ T-regulatory cells. J Immunother (2006) 2.86
Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia. Blood (2012) 2.52
Major cancer regressions in mesothelioma after treatment with an anti-mesothelin immunotoxin and immune suppression. Sci Transl Med (2013) 2.39
Immunotoxin treatment of cancer. Annu Rev Med (2007) 2.36
Improved cytotoxic activity toward cell lines and fresh leukemia cells of a mutant anti-CD22 immunotoxin obtained by antibody phage display. Clin Cancer Res (2002) 2.30
Both variant and IGHV4-34-expressing hairy cell leukemia lack the BRAF V600E mutation. Blood (2011) 2.28
Phase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B-cell malignancies. J Clin Oncol (2005) 2.16
Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia. J Clin Oncol (2012) 2.15
Myelodysplasia in autosomal dominant and sporadic monocytopenia immunodeficiency syndrome: diagnostic features and clinical implications. Haematologica (2011) 1.89
Phase II trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with hairy cell leukemia. J Clin Oncol (2009) 1.86
Localization of mesothelin in epithelial ovarian cancer. Appl Immunohistochem Mol Morphol (2005) 1.84
Minimal residual disease: what are the minimum requirements? J Clin Oncol (2014) 1.76
A protease-resistant immunotoxin against CD22 with greatly increased activity against CLL and diminished animal toxicity. Blood (2008) 1.74
Anti-CD22 immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-positive hematologic malignancies of childhood: preclinical studies and phase I clinical trial. Clin Cancer Res (2010) 1.64
Vaccine-induced tumor-specific immunity despite severe B-cell depletion in mantle cell lymphoma. Nat Med (2005) 1.63
VH4-34+ hairy cell leukemia, a new variant with poor prognosis despite standard therapy. Blood (2009) 1.59
Flow cytometric minimal residual disease monitoring in patients with multiple myeloma undergoing autologous stem cell transplantation: a retrospective study. Leuk Lymphoma (2008) 1.57
Evidence of canonical somatic hypermutation in hairy cell leukemia. Blood (2011) 1.55
In vitro antibody evolution targeting germline hot spots to increase activity of an anti-CD22 immunotoxin. J Biol Chem (2004) 1.54
Treatment of hematologic malignancies with immunotoxins and antibody-drug conjugates. Cancer Res (2011) 1.54
EBV-related lymphoproliferative disease complicating therapy with the anti-CD2 monoclonal antibody, siplizumab, in patients with T-cell malignancies. Clin Cancer Res (2009) 1.53
Administration of a CD25-directed immunotoxin, LMB-2, to patients with metastatic melanoma induces a selective partial reduction in regulatory T cells in vivo. J Immunol (2007) 1.52
Phase I study of recombinant human interleukin-7 administration in subjects with refractory malignancy. Clin Cancer Res (2010) 1.44
Recombinant immunotoxin engineered for low immunogenicity and antigenicity by identifying and silencing human B-cell epitopes. Proc Natl Acad Sci U S A (2012) 1.42
Characterization of the B cell epitopes associated with a truncated form of Pseudomonas exotoxin (PE38) used to make immunotoxins for the treatment of cancer patients. J Immunol (2006) 1.42
New monoclonal antibodies to mesothelin useful for immunohistochemistry, fluorescence-activated cell sorting, Western blotting, and ELISA. Clin Cancer Res (2005) 1.39
Immunotoxins for leukemia. Blood (2014) 1.33
HA22 (R490A) is a recombinant immunotoxin with increased antitumor activity without an increase in animal toxicity. Clin Cancer Res (2005) 1.32
Bortezomib resistance in mantle cell lymphoma is associated with plasmacytic differentiation. Blood (2010) 1.30
Recombinant immunotoxin against B-cell malignancies with no immunogenicity in mice by removal of B-cell epitopes. Proc Natl Acad Sci U S A (2011) 1.29
Variables affecting the quantitation of CD22 in neoplastic B cells. Cytometry B Clin Cytom (2010) 1.21
Cytotoxicity of the anti-CD22 immunotoxin HA22 (CAT-8015) against paediatric acute lymphoblastic leukaemia. Br J Haematol (2010) 1.19
Induction of caspase-dependent programmed cell death in B-cell chronic lymphocytic leukemia by anti-CD22 immunotoxins. Blood (2003) 1.17
Phase I trial of a novel diphtheria toxin/granulocyte macrophage colony-stimulating factor fusion protein (DT388GMCSF) for refractory or relapsed acute myeloid leukemia. Clin Cancer Res (2002) 1.15
Flow cytometry detection of minimal residual disease in multiple myeloma: Lessons learned at FDA-NCI roundtable symposium. Am J Hematol (2014) 1.15
CAT-8015: a second-generation pseudomonas exotoxin A-based immunotherapy targeting CD22-expressing hematologic malignancies. Clin Cancer Res (2009) 1.10
Minimal residual disease detection in hairy cell leukemia. Comparison of flow cytometric immunophenotyping with clonal analysis using consensus primer polymerase chain reaction for the heavy chain gene. Am J Clin Pathol (2003) 1.09
Flow cytometric immunophenotypic profiles of mature gamma delta T-cell malignancies involving peripheral blood and bone marrow. Cytometry B Clin Cytom (2005) 1.08
Modeling progression risk for smoldering multiple myeloma: results from a prospective clinical study. Leuk Lymphoma (2013) 1.06
Minimal residual disease testing in multiple myeloma by flow cytometry: major heterogeneity. Blood (2013) 1.06
FCRL1 on chronic lymphocytic leukemia, hairy cell leukemia, and B-cell non-Hodgkin lymphoma as a target of immunotoxins. Blood (2007) 1.03
Flow cytometric immunophenotyping of cerebrospinal fluid. Curr Protoc Cytom (2008) 1.03
Selective elimination of human regulatory T lymphocytes in vitro with the recombinant immunotoxin LMB-2. J Immunother (2006) 1.03
Bioethical considerations of monoclonal B-cell lymphocytosis: donor transfer after haematopoietic stem cell transplantation. Br J Haematol (2007) 1.01
Characteristic CD103 and CD123 expression pattern defines hairy cell leukemia: usefulness of CD123 and CD103 in the diagnosis of mature B-cell lymphoproliferative disorders. Am J Clin Pathol (2011) 0.98
Immunoglobulin superfamily receptor translocation associated 2 protein on lymphoma cell lines and hairy cell leukemia cells detected by novel monoclonal antibodies. Clin Cancer Res (2005) 0.97
Distinguishing hairy cell leukemia variant from hairy cell leukemia: development and validation of diagnostic criteria. Leuk Res (2013) 0.97
Flow cytometry immunophenotyping of hematolymphoid neoplasia. Methods Mol Biol (2011) 0.96
Thrombotic microangiopathy with targeted cancer agents. Clin Cancer Res (2011) 0.96
Immunotoxin BL22 induces apoptosis in mantle cell lymphoma (MCL) cells dependent on Bcl-2 expression. Br J Haematol (2009) 0.92
Role of flow cytometry of peripheral blood and bone marrow aspirates in early myeloma. Semin Hematol (2011) 0.91
Adult T-cell leukemia/lymphoma: a cytopathologic, immunocytochemical, and flow cytometric study. Cancer (2002) 0.91
Costimulated tumor-infiltrating lymphocytes are a feasible and safe alternative donor cell therapy for relapse after allogeneic stem cell transplantation. Blood (2012) 0.90
Expression and purification of the recombinant diphtheria fusion toxin DT388IL3 for phase I clinical trials. Protein Expr Purif (2004) 0.90
Variable CD52 expression in mature T cell and NK cell malignancies: implications for alemtuzumab therapy. Br J Haematol (2009) 0.90
Minimal residual disease in hairy cell leukemia patients assessed by clone-specific polymerase chain reaction. Clin Cancer Res (2006) 0.89
Soluble CD22 as a tumor marker for hairy cell leukemia. Blood (2008) 0.88
Molecular variant of hairy cell leukemia with poor prognosis. Leuk Lymphoma (2011) 0.88
Novel anti-CD30 recombinant immunotoxins containing disulfide-stabilized Fv fragments. Clin Cancer Res (2002) 0.87
Somatic hypermutation and VH gene usage in hairy cell leukaemia. Br J Haematol (2006) 0.87
Releasable PEGylation of mesothelin targeted immunotoxin SS1P achieves single dosage complete regression of a human carcinoma in mice. Bioconjug Chem (2007) 0.86
The bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) blocks hairy cell leukaemia survival, proliferation and B cell receptor signalling: a new therapeutic approach. Br J Haematol (2014) 0.86
Large granular lymphocytic proliferation-associated cyclic thrombocytopenia. Am J Hematol (2005) 0.86
Flow cytometric immunophenotypic assessment of T-cell clonality by Vβ repertoire analysis: detection of T-cell clonality at diagnosis and monitoring of minimal residual disease following therapy. Am J Clin Pathol (2011) 0.85
Synergistic antitumor activity of anti-CD25 recombinant immunotoxin LMB-2 with chemotherapy. Clin Cancer Res (2011) 0.85
Detection of malignant hematopoietic cells in cerebral spinal fluid previously diagnosed as atypical or suspicious. Cancer (2006) 0.84
Immunotoxin therapy of hematologic malignancies. Semin Oncol (2003) 0.84